- Home
- RIGL vs BWFG Comparison
RIGL vs BWFG Comparison
Compare RIGL & BWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | BWFG |
|---|---|---|
| Founded | 1996 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 543.4M |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RIGL | BWFG |
|---|---|---|
| Price | $46.86 | $66.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $45.67 | ★ $55.00 |
| AVG Volume (30 Days) | ★ 288.3K | 48.1K |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.52% |
| EPS Growth | ★ 1867.68 | 261.79 |
| EPS | 1.32 | ★ 2.95 |
| Revenue | ★ $294,282,000.00 | $2,826,000.00 |
| Revenue This Year | N/A | $17.64 |
| Revenue Next Year | $12.75 | $6.21 |
| P/E Ratio | $35.21 | ★ $22.25 |
| Revenue Growth | ★ 64.15 | 43.96 |
| 52 Week Low | $24.84 | $40.45 |
| 52 Week High | $52.24 | $69.59 |
Technical Indicators
Market Signals| Indicator | RIGL | BWFG |
|---|---|---|
| Relative Strength Index (RSI) | 66.46 | 56.25 |
| Support Level | $40.05 | $65.64 |
| Resistance Level | $49.10 | $69.41 |
| Average True Range (ATR) | 1.92 | 1.58 |
| MACD | 0.36 | -0.52 |
| Stochastic Oscillator | 90.87 | 49.22 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.